Effects of atorvastatin on lipid profile and coagulation parameters

Citation
M. Demir et al., Effects of atorvastatin on lipid profile and coagulation parameters, CURR THER R, 62(10), 2001, pp. 691-698
Citations number
34
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
ISSN journal
0011393X → ACNP
Volume
62
Issue
10
Year of publication
2001
Pages
691 - 698
Database
ISI
SICI code
0011-393X(200110)62:10<691:EOAOLP>2.0.ZU;2-D
Abstract
Background: Hypercholesterolemia. is an important risk factor for coronary artery disease (CAD) and is associated with impaired endothelial function, hypercoagulability, and increased platelet activation. The ability of stati ns to reduce the mortality and morbidity associated with CAD may not be due entirely to their lipid-lowering effects. Objective: The aim of this study was to determine the effects of atorvastat in on lipid profile and coagulation parameters. Methods: Adults with documented hypercholesterolemia who did not respond to dietary intervention alone and had not been treated pharmacologically were enrolled. In accordance with the criteria of the American Heart Associatio n guidelines, patients began therapy with atorvastatin 10 mg/d. Total chole sterol (TC), low-density and high-density lipoprotein cholesterol (LDL-C an d HDL-C), triglycerides (TG), fibrinogen, prothrombin time (PT), activated partial thromboplastin time (aPTT), clot retraction time (CRT), and tissue plasminogen activator (t-PA) levels were determined at baseline and at week 12 of treatment. Results: A total of 8 men and 11 women (mean age, 57.2 +/- 10.0 years; rang e, 43-77 years) were included in the study. Significant reductions from bas eline in TC (baseline, 259.5 +/- 29.3 mg/dL; week 12, 186.2 +/- 39.9 mg/dL; -28%) and LDL-C (baseline, 177.5 +/- 24.5 mg/dL; week 12,115.6 +/- 35.0 mg /dL; -34%) were observed at the end of the study (P < 0.001). TG and HDL-C levels did not change significantly (P > 0.05). CRT was shortened but remai ned within the normal range (P < 0.05). t-PA levels decreased significantly (baseline, 9.6 +/- 3.4 ng/mL; week 12, 6.5 +/- 3.5 ng/mL; P < 0.001), wher eas PT, aPTT, and fibrinogen levels did not change significantly. Conclusions: The data from this study suggest that treatment with atorvasta tin decreases t-PA levels and CRT as well as lipid levels. The reduction in t-PA and CRT may be a result of improvements in previously impaired endoth elial function and coagulation.